MaaT Pharma SA (EPA:MAAT)

France flag France · Delayed Price · Currency is EUR
4.160
-0.070 (-1.65%)
At close: Dec 5, 2025
-46.67%
Market Cap 67.00M
Revenue (ttm) 3.92M
Net Income (ttm) -31.13M
Shares Out 16.11M
EPS (ttm) -2.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 102,032
Average Volume 73,808
Open 4.260
Previous Close 4.230
Day's Range 4.160 - 4.400
52-Week Range 3.550 - 9.960
Beta -0.07
RSI 57.53
Earnings Date Mar 30, 2026

About MaaT Pharma

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic hematopoietic stem cell transplantation; and MaaT03X for the treatment... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 67
Stock Exchange Euronext Paris
Ticker Symbol MAAT
Full Company Profile

Financial Performance

In 2024, MaaT Pharma's revenue was 3.22 million, an increase of 44.34% compared to the previous year's 2.23 million. Losses were -28.90 million, 46.6% more than in 2023.

Financial Statements

News

There is no news available yet.